Clinical Trial Update: A Long-Term Safety and Tolerability Extension Study Evaluating Atogepant for the Prevention of Chronic or Episodic Migraine [Phase 3]

View source ↗

Summary

Long-term safety and tolerability data from a Phase 3 extension study of atogepant for the prevention of episodic and chronic migraine have been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Migraine

Drugs mentioned

• Qulipta (atogepant)

Snippet

Sponsor: AbbVie | Conditions: Episodic Migraine, Chronic Migraine | Phase 3 | Status: COMPLETED